Role of statistical random-effects linear models in personalized medicine

Current Pharmacogenomics and Personalized Medicine

Volumn 10, Issue 1, 2012, Pages 22-32

  Diaz, Francisco J ^a   Yeh, Hung Wen ^a   de Leon, Jose ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b Eastern State Hospital   (United States)

Author keywords

Chronic diseases; Dosage individualization; Drug mixed linear models; Effect sizes; Empirical Bayesian feedback; Evidence farms; Pharmacokinetic modeling; Random effects linear models

Indexed keywords

CLOZAPINE; FLUOXETINE; FLUVOXAMINE; LAMOTRIGINE; NORCLOZAPINE; OLANZAPINE; PAROXETINE; PHENOBARBITAL; RISPERIDONE; VALPROIC ACID;

ALGORITHM; ARTICLE; BAYESIAN LEARNING; BLOOD SAMPLING; CHRONIC DISEASE; CLINICAL ASSESSMENT; COMPARTMENT MODEL; CONCEPTUAL FRAMEWORK; DOSE CALCULATION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; EFFECT SIZE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; INDIVIDUALIZATION; NONHUMAN; PERSONALIZED MEDICINE; PHARMACOGENOMICS; POPULATION MODEL; RANDOM EFFECTS LINEAR MODEL; RANDOMIZATION; SCHIZOPHRENIA; STATISTICAL MODEL; STEADY STATE;

EID: 84860298567     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/1875692111201010022     Document Type: Article

References (36)

1. Pillai G, Mentré F, Steimer J-L. Non-linear mixed effects modeling-from methodology and software development to driving implementation in drug development science. J Pharmacokinet Pharmacodyn 2005; 32: 161-83.
2. Hay MC, Weisner TS, Subramanian S, et al. Harnessing experience: exploring the gap between evidence-based medicine and clinical practice. J Eval Clin Pract 2008; 14: 707-13.
3. Oquendo MA, Baca-Garcia E, Artes A, et al. Hypothesis Generation in the 21st Century. Mol Psychiatr 2012; (in press).
4. Sheiner LB, Beal SL. Bayesian individualization of pharmacokinetics: Simple implementation and comparison with nonbayesian methods. J Pharm Sci 1982; 71: 1344-8.
5. Diaz FJ, Rivera TE, Josiassen, RC, et al. Individualizing drug dosage by using a random intercept linear model. Stat Med 2007; 26: 2052-73.
6. Diaz FJ, Cogollo M, Spina E, et al. Drug dosage individualization based on a random-effects linear model. J Biopharm Stat 2012; (in press). DOI: 10.1080/10543406.2010.547264.
7. Diaz FJ, Santoro V, Spina E, et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry 2008; 41: 81-91.
8. Botts S, Diaz FJ, Santoro, V, et al. Estimating the effects of comedications on plasma olanzapine concentrations by using a mixed model. Prog Neuro-Psychopharmacology Biol Psychiatry 2008; 32: 1453-8.
9. Hu C, Zhou H. An improved approach for confirmatory phase III population pharmacokinetic analysis. J Clin Pharmacol 2008; 48: 812-22.
10. Hu C, Zhang J, Zhou H. Confirmatory analysis for phase III population pharmacokinetics. Pharm Stat 2011; 10: 14-26.
11. de Leon J, Susce MT, Pan R-M, et al. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 2007; 40: 93-102.
12. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of interand intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 1998; 8: 283-9.
13. Kalow W, Endrenyi L, Tang BK. Repeat administration of drugs as a means to assess the genetic component in pharmacological variability. Pharmacology 1999; 58: 281-4.
14. Ozdemir V, Kalow W, Tothfalusi L, et al. Multigenic control of drug response and regulatory decision-making in Pharmacogenomics: The need for an upper-bound estimate of genetic contributions. Curr Pharmacogenomics Person Med 2005; 3: 53-71.
15. Henderson CR. Estimation of variance and covariance components. Biometrics 1953; 9: 226-52.
16. Olesen OV. Therapeutic drug monitoring of clozapine treatment. Therapeutic threshold value for serum clozapine concentrations. Clin Pharmacokinet 1998; 34: 497-502.
17. de Leon J, Diaz FJ, Rogers T, et al. A pilot study of plasma caffeine concentrations in a US sample of smoker and non-smoker volunteers. Prog Neuro-Psychopharmacology Biol Psychiatry 2003; 27: 165-71.
18. de Leon J, Diaz FJ. Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. Prog Neuro-psychoph 2003; 27: 1059-63.
19. Winter ME. Basic Clinical Pharmacokinetics. 4th Edition. Philadelphia: Lippincott Williams & Wilkins 2004.
20. Evans JP, Meslin EM, Marteau TM, et al. Deflating the genomic bubble. Science 2011; 331: 861-2.
21. Tucker G. Pharmacogenetics-expectations and reality. Brit Med J 2004; 329: 4-6.
22. Chakraborty, B. Dynamic treatment regimes for managing chronic health conditions: a statistical perspective. Am J Public Health 2011; 101: 40-5.
23. Henderson R, Ansell P, Alshibani D. Regret-regression for optimal dynamic treatment regimes. Biometrics 2010; 66: 1192-201.
24. Shao J. Mathematical Statistics, Second Edition. New York: Springer 2003.
25. de Leon J, Spina E, Diaz FJ. Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians. J Clin Psychopharm 2009; 29: 201-5.
26. de Leon J, Susce MT, Johnson M, et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr Res 2007; 92: 95-102.
27. Muñoz A, Xu J. Models for the incubation of AIDS and variations according to age and period. Stat Med 1996; 15: 2459-73.
28. Food and Drug Administration. Guidance for industry: Statistical approaches to establishing bioequivalence. Center for Drug Evaluation and Research 2001.
29. Rostami-Hodjegan A, Amin AM, Spencer EP, et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharm 2004; 24: 70-8.
30. Haring C, Fleischhacker WW, Schett P. Influence of patient-related variables on clozapine plasma levels. Am J Psychiat 1990; 147: 1471-5.
31. Jiao Z, Shi XJ, Li ZD, et al. Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients. Brit J Clin Pharmaco 2009; 68: 47-60.
32. de Leon J. Evidence-based medicine versus personalized medicine: are they enemies? J Clin Psychopharmacol 2012 (in press).
33. Ioannidis JP. Expectations, validity, and reality in omics. J Clin Epidemiol 2010; 63: 945-9.
34. de Leon J, Correa JC, Ruaño G, et al. Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. Schizophr Res 2008; 98: 40-6.
35. Diaz FJ, Meary A, Arranz MJ, et al. Acetyl-coenzyme A carboxylase α gene variations may be associated with the direct effects of some antipsychotics on triglyceride levels. Schizophr Res 2009; 115: 136-40.
36. de Leon J, Diaz FJ. Genetics of schizophrenia and smoking: an approach to studying their comorbidity based on epidemiological findings. Hum Genet 2011 Dec 22. [Epub ahead of print].